Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 7/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.95 |
| ▸ | BLM | P54132 | 4/20 | 0.78 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL13293462 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL65495 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL19680109 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL12210779 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL14311544 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL19665229 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL7862886 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL15502093 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL19665230 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3125 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22992 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6423298-B1 | — | — | None | — | — | US | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| CN-122036593-A | Preparation method of key intermediate of ipratropium hydrochloride | 山东丰金制药有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4739294-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4739295-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| CN-122016983-A | Method for detecting multiple drugs in hair | 公安部鉴定中心 | 2026-05-12 | — | — | CN | claimed |
| CN-122029285-A | Methods of treating hypertrophic cardiomyopathy with AAV gene therapy vectors and therapeutic formulations | 迪纳柯公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-1993009764-A1 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0309464-B1 | MEMBRANE LIPID COMPOSITION AND METHOD FOR ITS PREPARATION | PHARES PHARMACEUTICAL HOLLAND B.V. (NL) | 1992-12-09 | — | — | EP | claimed |
| US-5141674-A | Methods of preparing pro-liposome dispersions and aerosols | PHARES PHARMACEUTICAL RESEARCH N.V. (AN) | 1992-08-25 | — | — | US | claimed |
| EP-0470154-A1 | DRY POWDER INHALATION DEVICE. | RIKER LABORATORIES INC (US) | 1992-02-12 | — | — | EP | claimed |
| WO-1990013327-A1 | DRY POWDER INHALATION DEVICE | RIKER LABORATORIES, INC. (US) | 1990-11-15 | — | — | WO | claimed |
| WO-1990013328-A1 | DRY POWDER INHALATION DEVICE | RIKER LABORATORIES, INC. (US) | 1990-11-15 | — | — | WO | claimed |
| EP-0239798-B1 | NEW PHARMACEUTICAL COMPOSITIONS FOR INHALATION | CHIESI FARMACEUTICI S.p.A. (IT) | 1990-09-26 | — | — | EP | claimed |
| EP-0387647-A2 | High-dispersion pharmaceutical composition | Desitin Arzneimittel GmbH (DE) | 1990-09-19 | — | — | EP | claimed |
| EP-0309464-A1 | MEMBRANE LIPID COMPOSITION AND METHOD FOR ITS PREPARATION. | PHARES PHARM RES NV (NL) | 1989-04-05 | — | — | EP | claimed |
| WO-1987007502-A1 | COMPOSITION AND METHOD | PHARES PHARMACEUTICAL RESEARCH N.V. (AN) | 1987-12-17 | — | — | WO | claimed |